Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
16. Mai 2023 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep to Participate in the JMP Securities Life Sciences Conference
09. Mai 2023 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
02. Mai 2023 08:00 ET
|
Immutep Limited
Media Release Webinar to take place on Tuesday, May 9, 2023, at 11:30 AM ET SYDNEY, AUSTRALIA, May 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage...
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
01. Mai 2023 08:00 ET
|
Immutep Limited
Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO® in metastatic...
Immutep Quarterly Activities Report
27. April 2023 08:00 ET
|
Immutep Limited
Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast...
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
26. April 2023 10:00 ET
|
Immutep Limited
Media Release Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA, April ...
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
26. April 2023 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for...
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
17. April 2023 09:00 ET
|
Immutep Limited
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosisFirst time efti will be studied in neoadjuvant, non-metastatic cancer settingNovel...
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
31. März 2023 08:00 ET
|
Immutep Limited
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care...
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
30. März 2023 08:00 ET
|
Immutep Limited
Media Release Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patientsExpansion based on safety and strong initial efficacy...